Quick Takeaways:
- Dechra has launched Laverdia (verdinexor tablets), the first and only FDA-approved oral treatment for dogs diagnosed with lymphoma, offering an at-home option that can be used from Day 1 after diagnosis.
- Canine lymphoma is among the most common cancers in dogs, yet only around 20% of affected dogs are estimated to receive chemotherapy, highlighting the need for additional treatment options.
- Laverdia can be used following diagnosis, while awaiting chemotherapy, after relapse, or when standard multi-agent chemotherapy is not preferred, providing veterinarians and pet owners with greater treatment flexibility.
Why It Matters?
Dechra has launched Laverdia (verdinexor tablets), the first and only FDA‑approved oral treatment for dogs with lymphoma, enabling at‑home therapy that can start on Day 1 after diagnosis. Canine lymphoma is one of the most common cancers in dogs, yet only about 20% of affected dogs receive chemotherapy, underscoring the need for additional, accessible options. Laverdia can be used immediately after diagnosis, while awaiting chemotherapy, after relapse, or when standard multi‑agent chemotherapy is not preferred, giving veterinarians and pet owners greater flexibility in treatment planning.
Source: PRnewswire
